ÀÌÇöö ¸íÀÇ

´Ù¾çÇÑ Áø·á°æÇè°ú ¿¬±¸¸¦ ÅëÇÑ ´ç´¢º´ ¸ÂÃãÄ¡·á

ÀÌÇöö ¸íÀÇ

  • ¼Ò ¼Ó
    ¿¬¼¼ÀÌÇöö³»°úÀÇ¿ø ³»ºÐºñ³»°ú
  • Àü¹®ºÐ¾ß
    ´ç´¢º´, °íÇ÷¾Ð, °©»ó¼±, °íÁöÇ÷Áõ, °ñ´Ù°øÁõ

´ç´¢º´ ºÐ¾ß ¸íÀÇ·Î Àß ¾Ë·ÁÁø ÀÌÇöö ¿øÀåÀº 33³âµ¿¾È ¿¬¼¼ÀÇ´ë ¼¼ºê¶õ½ºº´¿ø ³»ºÐºñ³»°ú ±³¼ö·Î ÀçÁ÷Çϸç ÀÓ»óÀÇ»ç·Î¼­, ÀÇÇб³À°Àڷμ­, ±×¸®°í ¿­Á¤ÀûÀÎ ¿¬±¸Àڷμ­ ´ç´¢º´ÇÐ ¹ßÀü¿¡ Å©°Ô °øÇåÇß½À´Ï´Ù. 1985³â ¹Ì±¹ ÇϹöµå Àǰú´ëÇÐ ºÎ¼Ó Á¶½½¸° ´ç´¢º´¼¾ÅÍ¿¡¼­ ´ç½Ã ¿ì¸®³ª¶ó¿¡¼­´Â ¿­¾ÇÇß´ø ºÐ¾ßÀÎ Ãéµµ¼¼Æ÷À̽Ŀ¡ ´ëÇÑ ¿¬±¸¸¦ ÇÏ°í µ¹¾Æ¿Í ´ç´¢º´ÇÐ ¹ßÀüÀÇ Åä´ë¸¦ ưưÈ÷ ´ÙÁ® ³õ¾ÒÀ¸¸ç, ²÷ÀÓ¾ø´Â ޱ¸Á¤½Å°ú ¿¬±¸¿¡ ´ëÇÑ ¿­Á¤À¸·Î ±¹³»¿Ü Àú³Î¿¡ ¾à 680¿©ÆíÀÇ ³í¹®À» ¹ßÇ¥ÇÏ¿´°í, ¸¹Àº Çмú»óÀ» ¼ö»óÇÏ¿´½À´Ï´Ù. »Ó¸¸ ¾Æ´Ï¶ó ±¹¹Î°Ç°­±³À°À» À§ÇÑ ¿©·¯ Àú¼ú Ȱµ¿¿¡µµ °ü¿©ÇÏ¿© ÀϹÝÀεéÀÌ ´ç´¢º´¿¡ ´ëÇØ Àß ÀÌÇØÇÒ ¼ö ÀÖµµ·Ï ±â¿©ÇÏ¿´½À´Ï´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ Çлç
  • ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ ´ëÇпø ¼®»ç
  • ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ ´ëÇпø ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ ³»°ú ±³¼ö
  • ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ ³»ºÐºñ¿¬±¸¼Ò ¼ÒÀå
  • ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ ÀÓ»óÀÇÇבּ¸¼¾ÅÍ ¼ÒÀå
  • ¼¼ºê¶õ½ºº´¿ø ´ç´¢º´¼¾ÅÍ ¼ÒÀå

¼ö»ó³»¿ª

Awards List
  • ÀÎÃÌ»ó
  • ¼³¿øÇмú»ó
  • Áö¼®¿µÀÇÇлó
  • º¸¿øÇмú»ó
  • °úÇбâ¼úÀÚ»ó
  • ÀÇÇÐÀÇ·áÀλó

ÇÐȸȰµ¿

Academic activities
  • 2004 ~ ´ëÇÑ´ç´¢º´ÇÐȸ ÀÌ»çÀå
  • 2007 ~ Çѱ¹ÁöÁúµ¿¸Æ°æÈ­ÇÐȸ ÀÌ»çÀå
  • 2010 ~ ÁöÁúµ¿¸Æ°æÈ­ÇÐȸ ȸÀå
  • 2012 ~ ´ëÇѳ»ºÐºñÇÐȸ ȸÀå
  • 2014 ~ ´ëÇÑÀÓ»ó³ëÀÎÀÇÇÐȸ ȸÀå
ÀÏÂ÷Áø·á¸¦ À§ÇÑ ´ç´¢º´ ¸Å´º¾ó
´ëÇ¥¼­Àû

ÀÏÂ÷Áø·á¸¦ À§ÇÑ ´ç´¢º´ ¸Å´º¾ó

  • ÀúÀÚ(±Û)ÀÌÇöö
  • ÃâÆÇ»ç°í·ÁÀÇÇÐ
  • ¹ßÇàÀÏ2015 ³â 11¿ù 10ÀÏ
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 7°Ç
Á¦ ¸ñ ´ç´¢º´¹é°ú
ÃâÆÇ»ç ÇöÁ¸ ¹ßÇàÀÏ 2017
Á¦ ¸ñ ÀÏÂ÷Áø·á¸¦ À§ÇÑ ´ç´¢º´ ¸Å´º¾ó
ÃâÆÇ»ç °í·ÁÀÇÇÐ ¹ßÇàÀÏ 2015
Á¦ ¸ñ ³ª Ȧ·Î Áö±¸ÃÌ ¿ÀÁö¿©Çà
ÃâÆÇ»ç ¿©ÇึÀÎµå ¹ßÇàÀÏ 2015
Á¦ ¸ñ ´ç´¢º´ÇÐ
ÃâÆÇ»ç °í·ÁÀÇÇÐ ¹ßÇàÀÏ 2005
Á¦ ¸ñ ¼¼·ÎÅä´Ñ°ú ¼ö¿ëüÀDZâÃÊ¿ÍÀÓ»ó
ÃâÆÇ»ç ¼¼·ÎÅä´Ñ¿¬±¸È¸ ¹ßÇàÀÏ 2005
Á¦ ¸ñ ½ÅÀåÀ̽Ä-À̷аú½ÇÁ¦-
ÃâÆÇ»ç ÀÇÇй®È­»ç ¹ßÇàÀÏ 2004
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Association between Metformin Use and Risk of Lactic Acidosis or Elevated Lactate Concentration in Type 2 Diabetes
¹ßÇ¥³âµµ 2017 ¹ßÇ¥Áö Yonsei Med J
Á¦ ¸ñ Association Between Heme Oxygenase-1 Promoter Polymorphisms and the Development of Albuminuria in Type 2 Diabetes: A Case-Control Study
¹ßÇ¥³âµµ 2015 ¹ßÇ¥Áö Medicine (Baltimore)
Á¦ ¸ñ The glycated albumin to glycated hemoglobin ratio might not be associated with carotid atherosclerosis in patients with type 1 diabetes
¹ßÇ¥³âµµ 2014 ¹ßÇ¥Áö Diabetes Metab J
Á¦ ¸ñ Inverse association between glycated albumin and insulin secretory function may explain higher levels of glycated albumin in subjects with longer duration of diabetes
¹ßÇ¥³âµµ 2014 ¹ßÇ¥Áö PLoS One
Á¦ ¸ñ Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes
¹ßÇ¥³âµµ 2014 ¹ßÇ¥Áö J Diabetes Investig
Á¦ ¸ñ Postprandial C-peptide to glucose ratio as a predictor of ¥â-cell function and its usefulness for staged management of type 2 diabetes
¹ßÇ¥³âµµ 2014 ¹ßÇ¥Áö J Diabetes Investig
Á¦ ¸ñ Anti-obesity effects of KR-66195, a synthetic DPP-IV inhibitor, in diet-induced obese mice and obese-diabetic ob/ob mice
¹ßÇ¥³âµµ 2014 ¹ßÇ¥Áö Metabolism

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

´ç´¢º´ÀÇ ¿øÀÎÀ» ±Ô¸íÇϰí ÇÕº´ÁõÀ» ¿¹¹æÇÒ ¼ö ÀÖ´Â Ä¡·áÁ¦ °³¹ßÀ» À§ÇØ ²÷ÀÓ¾øÀÌ Å½±¸ÇÏ°í ¿¬±¸Çϰí ÀÖ½À´Ï´Ù.

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

Áø·á¿¡ À־ °¡Àå Áß¿äÇÑ °ÍÀº ȯÀÚ¿ÍÀÇ ¼ÒÅë°ú ÀÌÇØ, ±×¸®°í ½Å·ÚÀÔ´Ï´Ù. ȯÀÚ ÇÑ ºÐ ÇÑ ºÐÀÇ ÀÛÀº º¯È­³ª ºÒÆíÇÔÀ» µè°í ±× ºÐÀÇ »óÅÂ¿Í »óȲÀ» ±íÀÌ ÀÌÇØÇÏ¿© Á¤È®ÇÑ Áø´ÜÀ» ³»¸®°í, ȯÀÚ Áß½ÉÀÇ ¸ÂÃã Ä¡·á°èȹÀ» ¼¼¿ì°í, ÇÔ²² Áö¼ÓÀûÀÎ °ü¸®¸¦ ÇØ³ª°¡´Â °ÍÀÌ Áß¿äÇÏ´Ù°í »ý°¢ÇÕ´Ï´Ù.

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

30¿©³â°£ ¼ö¸¹Àº ´ç´¢º´ ȯÀÚµéÀ» Áø·áÇϸ鼭 ¾òÀº °æÇè°ú ´Ù¾çÇÑ ¿¬±¸ ¼º°ú¸¦ ¹ÙÅÁÀ¸·Î °³°³Àο¡°Ô ¸Â´Â ¸ÂÃãÇü Ä¡·á¸¦ Á¦°øÇϰí ÇÕº´ÁõÀ» ¿¹¹æÇÏ¿© ȯÀںеéÀÇ »îÀÇ ÁúÀ» ³ôÀ̱â À§ÇØ ÃÖ¼±À» ´ÙÇϰڽÀ´Ï´Ù.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

¿¬¼¼ÀÌÇöö³»°úÀÇ¿ø

ÀÇ¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
02-337-7570
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

¿¬¼¼ÀÌÇöö³»°ú´Â ´ç´¢º´, °íÇ÷¾Ð, °ñ´Ù°øÁõ, °íÁöÇ÷Áõ, °©»ó¼± µî ³»ºÐºñÁúȯÀ» ÁßÁ¡ÀûÀ¸·Î Áø·áÇÏ´Â ÀÇ¿øÀ¸·Î ´ç´¢º´ ºÐ¾ß ¸íÀÇ·Î ¾Ë·ÁÁø ÀÌÇöö ±³¼ö°¡ ¿¬¼¼ÀÇ´ë ÅðÀÓ ÈÄ 2015³â¿¡ °³¿øÇÏ¿´½À´Ï´Ù. ¼¼ºê¶õ½ºº´¿ø¿¡¼­ 30¿©³â°£ ³»ºÐºñ³»°ú ±³¼ö·Î ÀçÁ÷ÇÏ¸ç ½×Àº ´Ù¾çÇϰí dzºÎÇÑ Áø·á°æÇè°ú Àü¹®ÀûÀÎ Áö½ÄÀ¸·Î ȯÀÚ ÇÑ ºÐ ÇÑ ºÐ ÃÖ¼±À» ´ÙÇØ Áø·áÇÕ´Ï´Ù.

¿¬¼¼ÀÌÇöö³»°úÀÇ¿ø À̹ÌÁö

¼­¿ïƯº°½Ã ¸¶Æ÷±¸ ¼­°­·Î 133, º´¿ìºôµù 4Ãþ

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä